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Neuropathic painIn neuropathic pain the repeated minocycline treatment inhibited the mRNA and protein expression of the
microglial markers and metalloproteinase-9 (MMP-9). The minocycline diminished the pronociceptive (IL-6,
IL-18), but not antinociceptive (IL-1alpha, IL-4, IL-10) cytokines at the spinal cord level. In vitro primary cell
culture studies have shown thatMMP-9, TIMP-1, IL-1beta, IL-1alpha, IL-6, IL-10, and IL-18 are ofmicroglial origin.
Minocycline reduces the production of pronociceptive factors, resulting in a more potent antinociceptive effect.
This change in the ratio between pro- and antinociceptive factors, in favour of the latter may be the mechanism
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Studies conﬁrm the complexity of endogenous factors that initiate
and regulate neuropathic pain conditions (Austin and Moalem-Taylor,
2010). Substances with diverse mechanisms of action that modulate
the neuroimmune system have been shown to relieve neuropathic
pain. One of these substances is minocycline, an antibiotic that belongs
to the group of semisynthetic tetracyclines and has been used for
30 years (Yong et al., 2004). Minocycline has antiinﬂammatory,
antiapoptotic, and immunomodulatory properties (Golub et al., 1991,
1992; Greenwald and Golub, 1993; Zemke and Majid, 2004; Sapadin
and Fleischmajer, 2006; Kielian et al., 2007). Minocycline also has
neuroprotective activity (Kim and Suh, 2009), as demonstrated in
numerous neurodegenerative disease models in mice and rats (Du
et al., 2001; Brundula et al., 2002; Nessler et al., 2002; Thomas and Le,
2004). Many reports revealed that minocycline administration
diminished the development of neuropathic pain (Raghavendra
et al., 2003; Ledeboer et al., 2005a,b; Mika et al., 2007, 2009).
In 2006, Piao et al. reported that the molecular mechanism of
minocycline action consists of inhibiting p38mitogen-activated protein
kinases (p38MAPKs) inmicroglial cells, while recent publications suggest
that minocycline also inhibits the activity of metalloproteinase (MMP-9)
(Niimi et al., 2013). These two molecular minocycline targets could becademy of Sciences,
Poland. Tel.: +48 12
Sciences PL6750001828. Ptargeted for the development of new treatments for neuropathic pain.
p38MAPK has a signiﬁcant contribution to neuropathic pain, and high
levels of p38MAPK are observed inmicroglia in neuropathic pain models
(Jin et al., 2003; Tsuda et al., 2004; Hains andWaxman, 2006; Clark et al.,
2007; Hains andWen et al., 2007). The activation of p38MAPK occurs as
the result of the activity of cytokines (IL-1beta, TNFalpha), triggering the
production of pronociceptive agents, such as nitrogen oxide, IL-1beta,
IL-6, and IL-18 (DeLeo and Yezierski, 2001; Miyoshi et al., 2008).
Increased p38 MAPK activity leads to the activation of a number of
transcription factors that regulate the expression of genes involved
in nociception (Potucek et al., 2006). During neuropathy, neurons
and glia exchange signals through chemokines, cytokines and the
complement system (Mika, 2008; Austin and Moalem-Taylor, 2010).
Antiinﬂammatory cytokines such as IL-1alpha, IL-4, or IL-10 play an
important role in nociception, thereby inhibiting the development of
neuropathic pain. Pain develops due to a disturbance in the equilibrium
between algesic and analgesic factors. In 2008, Kawasaki et al.
demonstrated the crucial role of MMP-9 in the development of neuro-
pathic pain, and the intrathecal administration of MMP-9 leads to the
development of allodynia, activation of microglial cells, and p38MAPK
upregulation. Administration of the tissue inhibitor of metalloproteinase
1 (TIMP-1) blocked the development of neuropathy. The authors suggest
that MMP-9 enhances nociception by transforming inactive proIL-1beta
to the active 1beta form.
The use of substances inhibiting microglial activation and formation
of proinﬂammatory cytokines, namely minocycline, pentoxifylline, or
propentofylline, inhibits the development of neuropathic pain
(Neuner et al., 1994; Lundblad et al., 1995; Sweitzer et al., 2001;ublished by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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appears to be a very interesting substance that, on the one hand,
reduces microglial activation by inhibiting the activity of p38MAPK in
microglial cells (Piao et al., 2006) and, on the other hand, suppresses
MMP-9 activity that was recently shown in experimental autoimmune
encephalomyelitis models (Niimi et al., 2013).
The objective of our studies was to assess whether and how
minocycline, which inhibits the development of neuropathic pain by
inhibiting microglia activation (Mika et al., 2010), affects the activation
of CD40-positive cells in the spinal cord and DRG during neuropathic
pain. Simultaneously, we studied the effect of minocycline on the
biosynthesis of proinﬂammatory cytokines (IL-1beta, IL-6, IL-18) and
antiinﬂammatory cytokines (IL-1alpha, IL-10, IL-4) as well as MMP-9
andMMP-2 and TIMP-1 and TIMP-2. The objective of the in vitro studies
was to determinewhether the above factors involved in the development
of neuropathic pain changed in LPS-treated primary microglia cell
cultures. In addition, the efﬁcacy of intrathecal MMP-9 inhibitor
(MMP-9 INH.I) and p38MAPK inhibitor (SB203580) was compared.
2. Experimental procedures
2.1. Animals
Male Wistar rats (300–350 g) from Charles River (Hamburg,
Germany) were housed in cages lined with sawdust under a standard
12/12 h light/dark cycle (lights on at 08:00 h) with ad libitum access
to food and water. All experiments were performed according to the
recommendations of the International Association for the Study of
Pain (IASP) (Zimmermann, 1983) and the National Institutes of Health
Guide for the Care andUse of Laboratory Animals, and these experiments
were approved by the local Bioethics Committee (Krakow, Poland).
2.2. Surgical preparations
Intrathecal (i.t.) catheters were chronically implanted in rats
according to themethods of Yaksh and Rudy (1976) under pentobarbital
anaesthesia (60 mg/kg; i.p.). The catheter (PE 10, INTRAMEDIC, Clay
Adams, Becton Dickinson and Company, Rutherford, NJ, USA) was
sterilised by immersion in 70% ethanol and fully ﬂushed with sterile
water prior to insertion. The catheter was carefully introduced through
the atlanto-occipital membrane to the subarachnoid space at the rostral
level of the spinal cord lumbar enlargement (L4–L6). Water for injection
or respective drugs were delivered slowly (1–2 min) in a volume of 5 μl
through the i.t. catheter, followed by 10 μl of water, which ﬂushed the
catheter. The injury to the sciatic nerve was performed ﬁve days after
catheter implantation.
Chronic constriction injury (CCI) was performed according to
Bennett and Xie (1988). The right sciatic nerve was exposed under
sodium pentobarbital anaesthesia (60 mg/kg; i.p.). Four ligatures
(4/0 silk) were made around the nerve, distal to the sciatic notch
with 1 mm spacing, until a brief twitch in the respective hind limb
was observed. After surgery, all rats developed symptoms of long-
lasting neuropathic pain, such as allodynia and hyperalgesia.
2.3. Drug administration and experimental scheme
Minocycline hydrochloride (30 mg/kg; Sigma, Schnelldorf, Germany)
was dissolved in water for injections and administered preemptively by
intraperitoneal (i.p.) injections 16 and 1 h before CCI and then twice
daily for seven days, as we previously described (Mika et al., 2007,
2009). This method of minocycline administration was used throughout
the study and is referred to in the text as “repeated administration”. This
administration schedule was used because systemic microglia inhibitors
attenuate the activation of microglia more efﬁciently when the inhibitor
is injected before injury (Raghavendra et al., 2003; Ledeboer et al., 2005a,
b;Mika et al., 2009) and repeatedly. For pharmacological studies, MMP-9INH.I (5 μg/5 μl; Merc Darmstadt, Germany) and 4-(4-ﬂuorophenyl)-2-
(4-methylsulfonylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580;
5 μg/5 μl; Sigma, Schnelldorf, Germany) were i.t. administered
preemptively 16 and 1 h before CCI, then once daily for seven days.
The inhibitors of MMP-9 and p38MAPK were dissolved in DMSO
according to the previously published data (Tsuda et al., 2004). The
control groups received vehicle according to the same schedule.
Naïve animals were processed (behavioural tests and tissue collection)
in parallel to the V-CCI and MC-CCI groups with the exception of CCI
surgery and anaesthesia.
2.4. Behavioural tests
2.4.1. Tactile allodynia (von Frey test)
Allodynia was measured 60 min after the last administration of
minocycline (30 mg/kg) according to our previous study (Mika et al.,
2007). Other drugs were examined in the same time point (Fig. 5A).
Allodynia was measured using an automatic von Frey apparatus
(Dynamic Plantar Aesthesiometer Cat. No. 37400, Ugo Basile, Italy).
The animals were placed in plastic cages with wire net ﬂoors 5 min
before the experiment. The strengths of the von Frey stimuli used in
our experiments ranged up to 26 g. The ﬁlament was applied to the
midplantar surface of the ipsilateral hind paw, and measurements
were taken automatically as described by us previously (Mika et al.,
2007;Makuch et al., 2013). Therewas almost no response to the highest
strength (26 g) in the naïve animals. No signiﬁcantly different paw
reactions were observed between the contralateral hind paw of
CCI-exposed and naïve rats. Therefore, a line was drawn at this
value to represent the naïve animals in the ﬁgures.
2.4.2. Hyperalgesia (cold plate test)
The cold plate test was conducted 65 min after the last injection of
MMP-9 INH.I and SB203580 (Fig. 5A). Hyperalgesia was assessed
using the cold plate test (Cold/Hot Plate Analgesia Meter No. 05044, Co-
lumbus Instruments, USA) as previously described (Mika et al., 2007;
Makuch et al., 2013). The temperature of the cold plate was kept at
5 °C, and the cut-off latency was 30 s. The animals were placed on the
cold plate, and the time until the hind paw was lifted was recorded. In
the naïve rat group, the reaction of the ﬁrst hind paw lift wasmeasured.
In the rats subjected to nerve injury, the ipsilateral paw reacted ﬁrst.
2.5. Biochemical tests
2.5.1. Microglial cell cultures and treatments
Primary cultures of microglial cells were prepared from 1-day-old
Wistar rat pups as previously described (Zawadzka and Kaminska,
2005). Brieﬂy, cells were isolated from the rats' cerebral cortices and
were plated at a density of 3 × 105 cells/cm2 in a culture medium that
consisted of DMEM/Glutamax/high glucose (Gibco, USA) supplemented
with heat-inactivated 10% foetal bovine serum (Gibco, USA), 100 U/ml
penicillin, and 0.1 mg/ml streptomycin (Gibco, USA) on poly-L-lysine
coated 75 cm2 culture ﬂasks and were maintained at 37 °C and 5%
CO2. The culture medium was changed after 4 days. The loosely
adherent microglial cells were recovered after 9 days by mild shaking
and centrifugation. The microglial cells were suspended in a culture
mediumand plated at a ﬁnal density of 2 × 105 cells onto 24-well plates
for mRNA analysis. Adherent cells were incubated for 48 h in a culture
medium before being analysed. Primary microglial cell cultures were
treated with LPS [100 ng/ml] (Sigma-Aldrich) for 6 h. Cell speciﬁcity
was determined in cultures of primary microglia by Western blot assay
using an antibody to OX-42 (microglial marker) and by qRT-PCR using
primers for C1q (a microglial marker) and GFAP (an astroglial marker).
The homogeneity of the microglial population was high (more than 95%
positive for OX-42 and C1q), and our homogeneity was similar to that
obtained by Zawadzka and Kaminska (2005).
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The ipsilateral sides of the dorsal lumbar (L4–L6) spinal cord and
DRG (L4–L6) were collected immediately after decapitation on day 7
after CCI (4 h after the last drug administration). The tissue samples
were placed in individual tubes containing the tissue storage reagent
RNAlater (Qiagen Inc.) and were stored at−70 °C until RNA isolation.
Total RNA was extracted using the TRIzol reagent (Invitrogen) as previ-
ously described (Chomczynski and Sacchi, 1987). TheRNA concentration
was measured using a NanoDrop ND-1000 Spectrometer (NanoDrop
Technologies), and the RNA quality was determined by chip-based
capillary electrophoresis using an RNA 6000 Nano LabChip Kit and an
Agilent Bioanalyzer 2100 (Agilent) according to the manufacturer's
instructions.
2.5.3. Quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR)
Reverse transcription was performed on 2 μg of total RNA (for tissue
analysis) and 500 ng (for cell culture analysis) using Omniscript reverse
transcriptase (Qiagen Inc.) at 37 °C for 60min. RT reactionswere carried
out in the presence of an RNAse inhibitor (rRNAsin, Promega) and an
oligo(dT16) primer (Qiagen Inc.). The cDNA was diluted 1:10 with
H2O, and for each reaction ~50 ng of cDNA synthesised from the total
RNA of an individual animal was used for the quantitative real-time
PCR (qRT-PCR) reaction. qRT-PCR was performed using Assay-On-
Demand TaqMan probes according to the manufacturer's protocol
(Applied Biosystems), and the reactions were performed on an
iCycler device (BioRad, Hercules). The following TaqMan primers
and probes were used: Rn01527838_g1 (Hprt, hypoxanthine
guanine rat hypoxanthine guanine phosphoribosyl transferase);
Rn01423590_m1 (CD40); Rn00579162_m1 (MMP-9, metalloproteinase
9); Rn01538170_m1 (MMP-2, metalloproteinase 2); Rn00587558_m1
(TIMP-1, metallopeptidase inhibitor 1); Rn00587558_m1 (TIMP-2,
metallopeptidase inhibitor 2); Rn00580432_m1 (IL-1beta, interleukin
1 beta); Rn00561420_m1 (IL-6, interleukin 6); Rn01422083_m1
(IL-18, interleukin 18); Rn00566700_m1 (IL-1 alpha, interleukin 1
alpha); Rn01456866_m1 (IL-4, interleukin 4); Rn00563409_m1 (IL-10,
interleukin 10).
The ampliﬁcation efﬁciency for each assay (between 1.7 and
2) was determined by running a standard dilution curve. The cycle
threshold values were calculated automatically using the iCycler IQ
3.0 softwarewith the default parameters. RNA abundancewas calculated
as 2-(threshold cycle). Because the HPRT transcript levels do not signiﬁcantly
change in rats exposed to CCI (Korostynski et al., 2006;Mika et al., 2008),
they served as an adequate housekeeping gene.
2.5.4. Western blot analysis
Ipsilateral, dorsal rat spinal cords (L4–L6) were collected 6 h after
the last minocycline treatment for protein analyses. Tissue lysates
were collected in RIPA buffer with a protease inhibitor cocktail and
cleared by centrifugation (14,000 ×g for 30 min, 4 °C). Samples
containing 20 μg of protein were heated in a loading buffer (50 mM
Tris–HCl, 2% SDS, 2% β-mercaptoethanol, 4% glycerol and 0.1%
bromophenol blue) for 8 min at 98 °C and were resolved on 10–20%
or 4–20% Criterion™ TGX™ pre-cast polyacrylamide gels. Following
gel electrophoresis, the proteins were transferred to Immune-Blot
PVDF membranes (Bio-Rad) with semi-dry transfer (30 min, 25 V).
The membranes were blocked for 1 h at RT using 5% non-fat dry milk
(Bio-Rad) in Tris-buffered saline with 0.1% Tween 20 (TBST), washed
in TBST, incubated overnight at 4 °C with primary antibodies (rabbit
polyclonal anti-IBA1, 1:500, ProteinTech; rabbit polyclonal anti-MMP-
9, 1:500, Millipore; mouse polyclonal anti-GAPDH, 1:5000 as loading
control, Millipore), and incubated for 1 h at RT with a secondary goat
polyclonal antibody conjugated to horseradish peroxidase (goat anti-
rabbit IgG, 1:5000, BioRad). Both primary and secondary antibodies
were diluted in solutions from SignalBoost Immunoreaction Enhancer
Kit (Merck Millipore). The membranes were washed for 2 × 2 minand 3 × 5 min with TBST. Immunocomplexes were detected using
an Immun-Star HRP Chemiluminescent Substrate Kit (BioRad) and
visualised using a Fujiﬁlm LAS-4000 FluorImager system. The relative
levels of immunoreactivity were quantiﬁed using the Fujiﬁlm Multi
Gauge software.
2.5.5. Immunocytochemical analysis
The commercially available, speciﬁc anti-Iba-1 antibody was used.
The cells were vehicle- or LPS-stimulated for 6 h and then were ﬁxed
for 20 min in 4% paraformaldehyde in a 0.1 M phosphate buffer (PB,
pH 7.4) and incubated with primary antibody (rabbit anti-Iba-1,
1:500, ProteinTech) for 2 days at 4 °C. After three washes in PB, double
immunoﬂuorescence was revealed by incubation for 2 h in the
ﬂuorochrome-conjugated secondary antibody, Alexa Fluor 555
(Molecular Probes, USA) donkey anti-mouse, diluted 1:500 in 5%
NDS. Sections were then washed with PB and coverslipped with an
Aquatex mounting medium (Merck, Darmstadt, Germany). Sections
without primary antibodies were used as negative controls.
2.5.6. Statistical analysis
The behavioural data in Fig. 1 are presented in grams and seconds
(mean± SEM), and the groups contained the number of rats as follows:
naïve= 12; V-CCI = 9; MC-CCI = 11. The behavioural data in Fig. 5 are
presented also in grams and seconds (mean ± SEM), and the groups
contained the number of rats as follows: naïve = 12; V-CCI = 20;
DMSO-CCI = 7; MMP-9INH.I-CCI = 7; SB203580-CCI = 14. The
results of the experiments were evaluated using a one-way analysis of
variance (ANOVA). The data are presented as the mean ± SEM.
*p b 0.05, **p b 0.01 and ***p b 0.001 indicate a signiﬁcant difference
compared with the control group (naïve rats); #p b 0.05, ##p b 0.01
and ###p b 0.001 indicate a signiﬁcant difference compared with the
vehicle-treated CCI-exposed rats; &p b 0.05 and &&&p b 0.001 indicate
differences compared with the DMSO-treated CCI-exposed group.
The results of the qRT-PCR andWestern blot analyses are presented
as the fold change compared with the control group (naïve rats) and
were calculated for the ipsilateral sides of the spinal cords and DRGs
of the CCI-exposed rats. For the Western blot analysis the groups
contained the number of rats as follows: naïve = 6; V-CCI = 7; MC-
CCI = 7. The quantitative qRT-PCR data are presented as the mean ±
SEM and represent the normalised averages derived from the threshold
cycle in the qRT-PCR analysis of 10 to 12 samples for each group. For the
qRT-PCR analysis the groups contained the number of rats as follows:
naïve = 10; V-CCI = 12; MC-CCI = 12. The inter-group differences
were analysed using an ANOVA, followed by Bonferroni's multiple
comparison test. *p b 0.05, **p b 0.01 and ***p b 0.001 indicate a
signiﬁcant difference compared with the control group (naïve rats);
#p b 0.05 ##p b 0.01 and ###p b 0.001 indicate a signiﬁcant difference
compared with the vehicle-treated CCI-exposed rats.
The results of the primary microglia cultures are presented as the
fold change compared with the control group (naïve rats). The data
are presented as the mean ± SEM. Inter-group differences were
analysed with a t test. **p b 0.01 and ***p b 0.001 indicate differences
compared with the LPS-treated cells.
All graphs were prepared using the GraphPad Prism software
(version 5.0).
3. Results
3.1. The inﬂuence of repeated administration of minocycline on the
development of allodynia and on CD40, C1q mRNA in the spinal cord
and DRG 7 days after CCI
All CCI-exposed rats developed allodynia (Fig. 1A, B). In the von Frey
test, strong tactile allodynia on the paw ipsilateral to the injury was
observed on day seven after CCI. At this time, the ipsilateral paw
responded to a stimulation of 14.8 ± 0.7 g (Fig. 1B), and naïve rats
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allodynia from 14.8 ± 0.7 g to 21.2 ± 0.8 g (Fig. 1B).
In the spinal cord, CD40 mRNA (1.0 ± 0.05 vs. 3.4 ± 0.2) was
upregulated compared with that of naïve rats (Fig. 1C). Minocycline
diminished the level of CD40mRNA in the spinal cord from 3.4 ± 0.2
to 3.0 ± 0.2. Additionally, in the DRG, CD40 mRNA was signiﬁcantly
upregulated from 1.0 ± 0.04 to 1.4 ± 0.04 (Fig. 1D) in CCI-exposed
rats comparedwith naïve animals.Minocycline signiﬁcantly diminished
the level of CD40 in the DRG from 1.4 ± 0.04 to 1.17 ± 0.05 (Fig. 1D).
In the spinal cord (Fig. 1E), upregulation of C1q mRNA (1 ± 0.1 vs.
8.6 ± 0.5) was observed compared to naïve rats. Repeated treatment- V MC
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Fig. 1. Effect of minocycline (30 mg/kg; i.p.; 16 h and 1 h before CCI and then twice daily for
7 days) on the development of mechanical allodynia (A; von Frey test) and CD40mRNA
expression in the spinal cord (B) and DRG (C) on day 7 after CCI. Allodynia was assessed
60 min after the last drug administration, and the data are presented as the mean ± SEM
(9–12 rats per group). The data for the biochemical studies were analysed as fold changes
compared with controls and represent the normalised averages derived from the qRT-PCR
threshold cycles of 10–12 samples from each group. The inter-group differences were
analysed using an ANOVA with Bonferroni's multiple comparison test. *p b 0.05 and
***p b 0.001 indicate a signiﬁcant difference compared with the control (naïve rats); and
#p b 0.05, ##p b 0.01, and ###p b 0.001 indicate a signiﬁcant difference compared with the
V-CCI rats (ANOVA, Bonferroni's test). N, naïve; V, vehicle (water for injection); MC,
minocycline.with minocycline signiﬁcantly diminished (from 8.6 ± 0.5 to 4.8 ±
1.1) the level of C1q mRNA in the spinal cord. In the DRG (Fig. 1F)
upregulation of C1q mRNA (1 ± 0.3 vs. 6.0 ± 0.4) was observed
compared to naïve rats. Repeated treatmentwithminocycline signiﬁcant-
ly diminished (from 6.0 ± 0.4 to 3.0 ± 0.1) the level of C1q in the DRG.
3.2. The inﬂuence of repeated minocycline administration on MMP-9,
MMP-2, TIMP-1 and TIMP-2 mRNA in the spinal cord and DRG 7 days after
CCI
MMP-9 mRNA was upregulated in the spinal cord from 1 ± 0.1 to
2.7 ± 0.4 (Fig. 2A) and in the DRG from 1 ± 0.1 to 5.5 ± 1.1 (Fig. 2B)
compared with naïve rats. Minocycline diminished the levels of MMP-9
mRNA in the spinal cord from 2.7 ± 0.1 to 1.1 ± 0.1 and in the DRG
from 5.5 ± 1.1 to 2.9 ± 0.5 (Fig. 2A and B, respectively).
MMP-2mRNA was upregulated in the spinal cord from 1.0 ± 0.6 to
1.5 ± 0 (Fig. 2C) and in the DRG from 1 ± 0.06 to 1.35 ± 1.1 (Fig. 2D)
compared with naïve rats. Minocycline did not inﬂuence the level of
MMP-2 mRNA in the spinal cord (Fig. 2C) but decreased the level of
MMP-2 from 1.35 ± 1.1 to 1.0 ± 0.07 in the DRG (Fig. 2D).
TIMP-1mRNA was upregulated in the spinal cord from 1.0 ± 0.3 to
2.6 ± 0.2 (Fig. 2E) and in the DRG from 1 ± 0.03 to 1.9 ± 0.1 (Fig. 2F)
compared with naïve rats. Minocycline did not inﬂuence the level of
TIMP-1 mRNA in the spinal cord (Fig. 2E) but decreased the level of
TIMP-1 from 1.9 ± 0.1 to 1.6 ± 0.04 in the DRG (Fig. 2F).
In the spinal cord and DRG, no changes were observed in TIMP-2
mRNA compared with naïve rats (Fig. 2G, H). Minocycline did not
inﬂuence the level of TIMP-2 mRNA in either structure.
3.3. The inﬂuence of repeated minocycline administration on Iba-1 and
MMP-9 protein levels in the spinal cord level 7 days after CCI
In the spinal cord, Iba-1 protein was upregulated from 1.0 ± 0.07 to
3.2 ± 0.06 compared with naïve animals (Fig. 3A). Minocycline
decreased the level of microglial activation marker from 3.2 ± 0.06 to
2.3 ± 0.1 (Fig. 3A).
Similar to Iba-1 protein regulation, MMP-9 protein was upregulated
from 1.0 ± 0.006 to 1.3 ± 0.01 in the spinal cord. Minocycline
decreased the level of MMP-9 protein from 1.3 ± 0.01 to 1.2 ± 0.01
(Fig. 3B).
3.4. The inﬂuence of repeated minocycline administration on the transcrip-
tion levels of proinﬂammatory cytokines (IL-1beta, IL-6, IL-18) in the spinal
cord and DRG 7 days after CCI
IL-1betamRNA was upregulated from 1.0 ± 0.07 to 3.4 ± 0.3 in the
spinal cord (Fig. 4A) and from 1.0± 0.1 to 2.2± 0.1 in the DRG (Fig. 4B)
compared with naïve rats. Minocycline did not inﬂuence the observed
levels of IL-1betamRNA in the spinal cord or DRG.
IL-6 mRNA was upregulated from 1.0 ± 0.07 to 9.1 ± 2.0 in the
spinal cord (Fig. 4C) and from 1 ± 0.16 to 79.1 ± 4.2 in the DRG
(Fig. 4D) compared with naïve rats. Minocycline diminished the levels
of IL-6 mRNA from 9.1 ± 2.0 to 4.6 ± 1.0 in the spinal cord and from
79.1 ± 4.2 to 47.5 ± 5.2 in the DRG.
IL-18 mRNA was upregulated from 1.0 ± 0.6 to 1.2 ± 0.05 in the
spinal cord (Fig. 4E) and from 1 ± 0.1 to 2.2 ± 0.1 in the DRG
(Fig. 4F) compared with naïve rats. Minocycline diminished the levels
of IL-18mRNA in the spinal cord from 1.2 ± 0.05 to 1 ± 0.1 and in the
DRG from 2.2 ± 0.1 to 1.8 ± 0.1.
3.5. The inﬂuence of repeated minocycline administration on mRNA levels
of antiinﬂammatory cytokines (IL-1alpha, IL-4, IL-10) in the spinal cord
7 days after CCI
In the spinal cord, no changes in IL-1alpha mRNA (Fig. 4G) were
observed, but in the DRG, IL-1alpha mRNA was upregulated from 1 ±
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Fig. 2. Effects of minocycline (MC) on mRNA levels of pro- (MMP-9, MMP-2) and antiinﬂammatory factors (TIMP-1, TIMP-2) in the spinal cord and DRG during neuropathic pain.
Minocycline (30 mg/kg; i.p.; 16 h and 1 h before CCI and then twice daily for 7 days) diminished the mRNA expression of MMP-9 (A, B) in the dorsal part of the lumbar spinal cord
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61E. Rojewska et al. / Journal of Neuroimmunology 277 (2014) 57–660.1 to 29.9±2.8 (Fig. 4H) comparedwith naïve rats.Minocycline did not
inﬂuence these changes in IL-1alphamRNA in the spinal cord or DRG.
In the spinal cord and DRG, no changes in IL-4mRNAwere observed
compared with naïve rats (Fig. 4I, J). Minocycline did not inﬂuence the
levels of IL-4mRNA in either the spinal cord or DRG.
IL-10mRNAwas upregulated from 1± 0.2 to 4.4 ± 0.3 in the spinal
cord (Fig. 4K) and from 1 ± 0.2 to 7.3 ± 0.9 in the DRG (Fig. 4L)
compared with naïve rats. Minocycline did not inﬂuence these changes
in IL-10 mRNA in the spinal cord but decreased these changes in the
DRG from 7.3 ± 0.9 to 4.5 ± 0.5.
3.6. The inﬂuence of LPS stimulation on mRNA levels of pro- and
antiinﬂammatory factors in microglial cells — in vitro studies
Our immunocytochemical analyses showed changedmorphology of
microglial cell from a ramiﬁed (non-stimulated) to an amoeboid after
6 h LPS treatment. The mRNA levels for MMP-9, IL-1beta, IL-6, IL-18,
TIMP-1, TIMP-2, IL-1alpha and IL-10were signiﬁcantly upregulated 6 h
after LPS treatment (Table 1). The mRNA for IL-4was undetectable.
3.7. Comparison of analgesic effects of MMP-9 INH.I and SB203580 on CCI-
induced development of allodynia and hyperalgesia 7 days after CCI in rats
V- and DMSO-treated CCI-exposed rats developed similarly strong
allodynia and hyperalgesia compared to naïve rats as demonstrated in
the von Frey and cold plate tests (Fig. 5A, B, C).MMP-9 INH.I administration at a dose of 5 μg/5 μl attenuated the
development of allodynia from 12.2 ± 0.7 g to 16.2 ± 2.4 g (Fig. 5B)
and of hyperalgesia from 6.3 ± 0.5 s to 15.4 ± 2.3 s (Fig. 5C) on day 7
after CCI. We used the same dose to directly compare the effectiveness
of the MMP-9 INH.I with that of the p38MAPK inhibitor (SB203580).
The results obtained after SB203580 administration were weaker than
those of MMP-9 INH.I SB203580 attenuated the development of
allodynia from 11.8 ± 0.4 g to 13 ± 0.8 g (Fig. 5B) and of hyperalgesia
from 6.3 ± 0.5 s to 10.7 ± 0.9 s (Fig. 5C).
4. Discussion
Studies in recent years, including those conducted in our group,
suggest that repeated administrations of minocycline inhibit microglial
activation, as demonstrated using markers, such as CD40, C1q, Iba-1,
and OX42 (Chatzigeorgiou et al., 2009; Mika et al., 2009). This effect con-
tributes to the reduction of neuropathy development (Raghavendra et al.,
2003; Ledeboer et al., 2005a,b; Mika et al., 2007, 2010). Minocycline is an
interesting, biologically active substance that has potential therapeutic
use. However, the exact mechanism of minocycline action has not been
fully elucidated. Many reports, including those published by our group,
revealed that preemptive systemic minocycline administration dimin-
ished the development of neuropathic pain states (Raghavendra et al.,
2003; Ledeboer et al., 2005a,b;Mika et al., 2007, 2009), but did not reduce
pain that was already established (Raghavendra et al., 2003). Ledeboer
et al. (2005a,b) suggested thatmicroglia play a crucial role in initiating,
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62 E. Rojewska et al. / Journal of Neuroimmunology 277 (2014) 57–66rather than maintaining, enhanced pain responses. Our in vitro studies
revealed that the mRNA levels ofMMP-9, TIMP-1, IL-1beta, IL-1alpha, IL-
6, IL-10, and IL-18 are elevated in LPS-treated primary microglia rat cul-
tures. These results suggest the involvement of factors ofmicroglial origin
in the mechanism of minocycline pain inhibition. The analgesic effect of
minocyclinewas already thought to be due to the inhibition of the spinal-
ly activated proinﬂammatory cytokines IL-1beta and TNFalpha (Ledeboer
et al., 2005a,b). In 2006, Zanjani et al. observed that minocycline reduced
the serum concentrations of IL-6 following nerve injury. Our present
comprehensive studies on the involvement of neuroimmune factors
showed that the preemptive and repeated i.p. administration of
minocycline reduced theMMP-9, IL-6 and IL-18mRNA levels within the
spinal cord and DRG in CCI-exposed rats. Moreover, the TIMP-1,MMP-2
and IL-10mRNA levels were also diminished by minocycline in the DRG.
Piao et al. (2006) reported that the molecular mechanism of
minocycline consisted of p38MAPK inhibition within microglia, whileother authors demonstrated thatminocycline also inhibitedMMP-9 in is-
chemiamodels (Machado et al., 2006;Murata et al., 2008). In 2008,MMP-
9 upregulation in the DRG after spinal nerve ligation was demonstrated
(Kawasaki et al., 2008). We were the ﬁrst to demonstrate the signiﬁcant
upregulation ofMMP-9 and TIMP-1mRNA in the spinal cord and DRG of
CCI-exposed rats. These results conﬁrm the hypothesis proposed by
Kawasaki et al. (2008), who demonstrated that the intrathecal adminis-
tration of MMP-9 caused pain associated with microglial activation and
increased IL-1beta levels. As early as 1998, Schönbeck et al. suggested
that MMP-9 is an enzyme that converts proIL1beta into its active form,
i.e., IL-1beta (Schönbeck et al., 1998). The effect was not observed in
MMP-9 knock-out mice. Moreover, the administration of MMP-9 siRNA
reduced the development of neuropathy (Wang et al., 2000), and the in-
trathecal administration of anti-IL-1beta antibodies reduced MMP-9-
induced allodynia (Kawasaki et al., 2008). A hypothesis was formulated
that the nerve damage caused burst discharges within sensory neu-
rons, releasing MMP-9 and IL-1beta, which, upon being transformed
into the active form, enhanced the excitability of neurons. This sug-
gestion has been conﬁrmed in our studies (the mRNA levels of
MMP-9 and IL-1beta simultaneously increased). Minocycline re-
duced the level of the active IL-1beta form by reducing the level of
MMP-9 biosynthesis. In 2001, Rosenberg et al. demonstrated that
MMP-2 is produced by activated astrocytes and satellite cells
(Rosenberg et al., 2001). In 2009, we described the activation of astro-
cytes, which begins slowly around day 7. This result indicates that the
activation of astroglia follows the earlier activation of microglia in CCI-
exposed rats (Mika et al., 2009). Kawasaki et al. (2008) demonstrated
increases in MMP-2 levels within the DRG as late as day 10 following
spinal nerve ligation. As shown by our studies, on day 7 following sciatic
nerve ligation, a slight increase in theMMP-2mRNA levels is observed
within the spinal cord and DRG. However, we were unable to observe
upregulation in animals receiving repeatedminocycline administration,
suggesting that at the initial stages of neuropathic pain, MMP-2 may
originate from the microglia. This hypothesis is supported by the
fact that MMP-2 is produced by primarymicroglial cell cultures. The in-
trathecal administration of endogenous inhibitors of TIMP-1 and TIMP-
2 (inhibitors ofMMP-9 andMMP-2, respectively) strongly inhibited the
development of neuropathic pain. Our results suggest that the adminis-
tration of minocycline prevents the spinal upregulation ofMMP-9 and
MMP-2mRNA levels in CCI-subjected rats, thereby reducing the levels
of proinﬂammatory factors. The beneﬁcial effects of minocycline are
also due to the CCI-induced upregulation of antinociceptive factors.
TIMP-1 and TIMP-2 are not downregulated after injection, suggesting
that the drug restores the equilibrium. Considering the role of MMP-9
in the development of neuropathy, the activity of minocycline may re-
sult from its beneﬁcial effects, which are both analgesic and neuropro-
tective. Therefore, the MMP-9 INH.I was also used in our studies.
Following the intrathecal administration of MMP-9 INH.I, the devel-
opment of allodynia and hyperalgesia was impaired in our neuro-
pathic pain model. The intrathecal administration of MMP-9 leads
to a strong activation of p38MAPK in microglial cells (Kawasaki
et al. 2008) and these changes are similar to those observed in the
development of neuropathic pain (Jin et al., 2003). MMP-9-induced
allodynia can also be reduced by a p38MAPK inhibitor (FR167653)
(Kawasaki et al., 2008). In our studies, the MMP-9 INH.I had better
effectiveness under neuropathic pain then SB203580, a p38MAPK in-
hibitor, which is in agreement with others, who have shown that
SB203580 is very effective in the early phase (1–5 days after ligation
of the L5 spinal nerve) of neuropathic pain development (Jin et al.,
2003). Our data suggests that the analgesic effect of minocycline is
related to the inhibition of both MMP-9 and p38MAPK.
In our studies, we have focused on the proinﬂammatory interleukins
IL-6, IL-18 and IL-1beta, which are important for nociception. The latter
is known to be strongly activated upon neural damage (Hopkins and
Rothwell, 1995; Mika et al., 2008). The IL-1beta or IL-6 intrathecal
administration induces allodynia and hyperalgesia in rats (Oka et al.,
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Fig. 4. Effects of minocycline (MC) on themRNA levels of proinﬂammatory (IL-1beta, IL-6, IL-18) and antiinﬂammatory cytokines (IL-1alpha, IL-4, IL-10) in the spinal cord and DRG during
neuropathic pain. Minocycline (30 mg/kg; i.p.; 16 h and 1 h before CCI and then twice daily for 7 days) diminished themRNA expression levels of IL-6 (C, D) and IL-18 (E, F) in the dorsal
part of the lumbar spinal cord and in the DRG 7 days after CCI.Minocycline also inﬂuenced the levels of IL-10 (L)mRNA in the DRG. The data were analysed as fold changes comparedwith
controls and represent the normalised averages derived from the qRT-PCR threshold cycles of 10–12 samples from each group. The data are presented as the mean ± SEM. Inter-group
differences were analysed using Bonferroni's multiple comparison test. *p b 0.05, **p b 0.01, and ***p b 0.001 indicate differences comparedwith the naïve rats. #p b 0.05, ##p b 0.01, and
###p b 0.001 indicate differences compared with the CCI-exposed group. N, naïve; V, vehicle (water for injection); MC, minocycline.
63E. Rojewska et al. / Journal of Neuroimmunology 277 (2014) 57–661993; Oprée and Kress, 2000; Obreja et al., 2002; Mika et al., 2008). As
shown by our studies, sciatic nerve injury caused a strong increase in
the mRNA levels of IL-1beta at the spinal cord and DRG level, while
minocycline had no effect on these changes. IL-6 is secreted mainly
not only by monocytes and macrophages but also by microglial cells
(Kreutzberg, 1996; Milligan et al., 2003) and has been implicated in
neuropathic pain (De Jongh et al., 2003, Mika et al., 2008). In the
aetiology of numerous neurodegenerative and neuroimmune disorders
associated with pain symptoms, allodynia was correlated with the IL-6
immunoreactivity or mRNA levels within the sciatic nerve and DRG
(DeLeo et al., 1996; Gruol and Nelson, 1997; Osamura et al., 2005).
The importance of IL-6 in nociception has been further demonstratedin IL-6 knock-out mice, which do not develop hypersensitivity in
response to nerve injury (Ramer et al., 1998;Murphy et al., 1999). Studies
revealed that the intrathecal administration of IL-6 to naïve animals
caused allodynia (DeLeo et al., 1996). Our studies showed that sciatic
nerve ligation led to a signiﬁcant increase in the IL-6mRNA levels within
the spinal cord and the dorsal root ganglia on day 7 following CCI.
Minocycline administration prevented these changes, which is in agree-
ment with previous studies (Zanjani et al., 2006; Lee et al., 2010). In
2008, theﬁrst report suggesting an important role of IL-18 in neuropathic
pain was published. IL-18 is a proinﬂammatory cytokine that is observed
in numerous autoimmune diseases (Boraschi and Dinarello, 2006). Some
published data showed that administration of IL-18 leads to increased
Table 1
Proinﬂammatory and antiinﬂammatory factor expression in primarymicroglial cell cultures.
The mRNA levels of proinﬂammatory (MMP-9, MMP-2, IL-1beta, IL-6, IL-18) and
antiinﬂammatory (TIMP-1, TIMP-2, IL-1alpha, IL-4, IL-10) factors in non-stimulated and LPS-
treatedmicroglial primary cell cultures. The reverse transcriptase-polymerase chain reaction
shows that mRNA forMMP-9,MMP-2, IL-1beta, IL-6, IL-18, TIMP-1, TIMP-2, IL-1alpha, and IL-
10, but not IL-4, is expressed in rat primary microglial cell cultures. After 6 h, LPS-treatment
upregulated the mRNA forMMP-9, IL-1beta, IL-6, IL-18, TIMP-1, IL-1alpha, and IL-10, but not
forMMP-2 and TIMP-2. The mRNA level for IL-4 was undetectable. The data are presented
as the mean ± SEM. Inter-group differences were analysed using a t test. **p b 0.01 and
***p b 0.001 indicate differences comparedwith the LPS-treated cells. K/− (not stimulated),
K/+ (LPS-stimulated). Microphotographs – an immunocytochemistry analysis of microglial
cells – in vitro studies. Cell speciﬁcity was determined using commercially available Iba-1
(a microglial marker) antibody in immunocytochemistry. The scale bar for all microphoto-
graphs is 25 μm. The data from 3 cell cultures are presented.
Primary microglia cell
culture
K/− K/+
mRNA level (fold change of control)
IL-1beta 1 ± 0.1 55.1 ± 5.4***
IL-6 1 ± 0.2 17,822.0 ± 4365.0***
IL-18 1 ± 0.3 5.4 ± 0.5**
IL-1alpha 1 ± 0.3 321.1 ± 35.8***
IL-4 Not detected Not detected
IL-10 1 ± 0.4 20.5 ± 1.4**
MMP-9 1 ± 0.3 5.1 ± 0.8**
TIMP-1 1 ± 0.1 3.1 ± 0.4***
MMP-2 1 ± 0.2 1.1 ± 0.2
TIMP-2 1 ± 0.1 0.8 ± 0.1
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water for injection (V) and DMSO according to the same schedule. Inter-group differences
were analysed using ANOVA followed by Bonferroni's multiple comparison test. The data
are presented as the mean ± SEM (7–20 rats per group). Pain symptoms were assessed
60 min after the last drug administration. ***p b 0.001 indicates differences compared
with the naïve rats; &p b 0.05 and &&&p b 0.001 indicate differences compared with the
DMSO-treated CCI-exposed group. N, naïve; V, water for injection.
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released by microglial cells is responsible for the development of
allodynia (Miyoshi et al., 2008; Chu et al., 2012; Daigo et al. 2012),
which is consistent with our results. On day 7 following CCI, the IL-18
mRNA levels in the spinal cord and DRG increase and are reduced by
minocycline administration. Because the activation of the proinﬂammato-
ry cytokine IL-18 occurs via p38MAPK, the administration ofminocycline,
which is an inhibitor of that kinase, may reduce neuropathic pain.
Recently, an increasing number of studies have highlighted the
crucial role of proinﬂammatory cytokines in pain processes. The
intrathecal administration of IL-1alpha, in contrast to IL-1beta, is capable
of suppressing nociception (Binshtok et al., 2008; Mika et al., 2008). A
strong increase in the IL-1alpha levels was observed within the DRG
(Mika et al., 2008). Such a strong elevation of the IL-1alphamRNA levels
is important for reducing neuropathy; importantly, minocycline does
not inhibit this change. We also demonstrated a strong increase in IL-
10mRNA in the spinal cord and DRG that is not affected byminocycline.
As an antinociceptive cytokine, IL-10 affects microglial activation by
inhibiting the activation of IL-1beta and IL-6 and reducing the activation
of pronociceptive cytokine receptors (Moore et al., 1993; Sawada et al.,
1999). The fact that minocycline does not reduce the levels of these
antinociceptive factors is one of the reasons behind its analgesic effects.
IL-4 is also considered to be an antinociceptive cytokine (Vale et al.,
2003). However, no changes in IL-4mRNA levels were observed in our
study, similar to the study conducted by Wen Tao et al. (2011).
Proinﬂammatory factors produced by activated glia and immune
cells promote neuropathic pain conditions (Mika et al., 2013). At the
spinal cord level, themicroglia is highly activated, leading to the release
of proinﬂammatory substances, such as IL-1beta, IL-6, and IL-18, and
antiinﬂammatory substances, such as IL-10 and IL-1alpha. This hypothesis
corresponds well with our in vitro studies, where we have shown that
microglial cells produce IL-1beta, IL-6, IL-18, MMP-2 and MMP-9, TIMP-
1 and TIMP-2, IL-10 and IL-1alpha, while IL-4 is undetectable. In 2013Kobayashi et al. have shown the upregulation of IL-1beta mRNA induced
by LPS in microglia cell culture, which is in agreement with our results
(Kobayashi et al., 2013). The authors have also shown theparallel increase
of IL-1beta protein level as measured by ELISA. In the DRG, the immune
response is driven by macrophages, lymphocytes and satellite cells.
The recruitment and activity of the immune cells in the DRG upregulate
IL-1beta, IL-6, IL-18, and MMPs.
5. Conclusion
In summary, the development of neuropathic pain is the result of a
disrupted equilibrium between algesic and analgesic factors. We were
the ﬁrst to demonstrate the reversal of these changes through
minocycline as a result of reduced pronociceptive factor mRNA (IL-6
65E. Rojewska et al. / Journal of Neuroimmunology 277 (2014) 57–66and IL-18) within the spinal cord and DRG in a CCI model. Minocycline
had no impact on expression of antinociceptive factors, such as IL-
1alpha, IL-4 and IL-10 in the spinal cord and DRG, with the exception
of IL-10 within the DRG. We observed that minocycline restores the
neuroimmune balance that is biased towards pronociceptive factors in
the development of neuropathic pain. In addition, our study signiﬁcantly
broadens the knowledge on the effects of minocycline in neuropathic
pain and highlights the important role of MMP-9 as a factor involved
in the development of neuropathic pain. We were the ﬁrst to demon-
strate that minocycline affects MMP-9 mRNA within the spinal cord
andMMP-9,MMP-2 and TIMP-1mRNAwithin the DRG that are elevated
following CCI. These results provide a rational basis for the further
evaluation of minocycline in the treatment of neuropathic pain and
perhaps other MMP-9-dependent pathologies.
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